Lung cancer is the deadliest cancer worldwide, accounting for 1.82 million deaths in 2022. The second most deadly form of cancer is colorectum cancer, followed by liver cancer. However, lung cancer is only the sixth leading cause of death worldwide, with heart disease and stroke accounting for the highest share of deaths. Male vs. female cases Given that lung cancer causes the highest number of cancer deaths worldwide, it may be unsurprising to learn that lung cancer is the most common form of new cancer cases among males. However, among females, breast cancer is by far the most common form of new cancer cases. In fact, breast cancer is the most prevalent cancer worldwide, followed by prostate cancer. Prostate cancer is a very close second to lung cancer among the cancers with the highest rates of new cases among men. Male vs. female deaths Lung cancer is by far the deadliest form of cancer among males but is the second deadliest form of cancer among females. Breast cancer, the most prevalent form of cancer among females worldwide, is also the deadliest form of cancer among females. Although prostate cancer is the second most prevalent cancer among men, it is the fifth deadliest cancer. Lung, liver, stomach, colorectum, and oesophagus cancers all have higher deaths rates among males.

Introduction

Cancer Statistics: Cancer continues to be a major global health challenge, with significant increases in both incidence and mortality. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. The most common cancers included lung, breast, colorectal, prostate, and stomach cancers. The global cancer burden is projected to rise substantially, with estimates suggesting 35.3 million new cases and 18.5 million cancer-related deaths by 2050.

This increase is attributed to factors such as population growth, aging, and exposure to risk factors like tobacco use, obesity, and environmental pollutants. The economic impact of cancer is also profound, with direct medical costs in the United States alone reaching nearly $209 billion in 2020.

These statistics underscore the urgent need for enhanced prevention, early detection, and treatment strategies to address the growing cancer burden globally. The information is presented from a market researcher's point of view, incorporating the latest data and trends.

In 2020, Eastern Asia accounted for around 21 percent of deaths due to breast cancer worldwide. This statistic shows the distribution of breast cancer deaths among women worldwide, by region.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

In 2022, there were an estimated 2.48 million new cases of trachea, bronchus, and lung cancer worldwide. Breast cancer was the second most common cancer type at that time with around 2.3 million new cases worldwide.

Number of new cancer cases

Cancer can be caused by internal factors like genetics and mutations, as well as external factors such as smoking and radiation. It occurs in the presence of uncontrolled growth and spread of abnormal cells. However, many cancer cases could be prevented, for example, by omitting cigarette usage and heavy alcohol consumption. Risk of developing cancer tends to increase with age and is most common in older adults. Nevertheless, cancer can develop in individuals of any age. Cancer can be treated through surgery, radiation, and chemotherapy, among other methods.

In the United States, there will be an estimated two million new cancer cases and 611,720 deaths in 2024. Among U.S. men, prostate cancer and lung and bronchus cancers are the most common cancer types as of 2024, totaling an estimated 299,010 and 116,310 cases, respectively. In women, breast cancer and lung and bronchus cancer are the most common newly diagnosed types, totaling 310,720 and 118,270 cases, respectively.

In 2020, Melanesia was the region with the highest death rate due to breast cancer worldwide, with around 27.5 deaths per 100,000 women. This statistic shows the age-standardized mortality rate (deaths) of breast cancer among women worldwide, by region.

Cancer in Africa is a growing concern. The number of new cases reported on the continent amounted to over **** million in 2022. Breast cancer had the highest number of new cases, with ******* reported incidences of cancer. This demonstrated an increase of *** percent compared to 2020. Cervical cancer and prostate cancer followed, with around ******* and over ******* cases, respectively. Cervical cancer’s ranking in Africa is significantly higher than the new cases of cancer reported worldwide, and this is likely due to its prevalence in women living with HIV. Women who have contracted HIV are also more prone to having a human papillomavirus (HPV) infection, which is generally linked with cervical cancer. Deaths related to cancer Of almost *** million cancer-related diagnoses in Africa in 2022, ******* deaths were registered. Breast cancer was the highest contributor to the number of deaths, with ****** cases. On a global scale, African women contributed around ** percent to the global number of deaths related to breast cancer among females. However, deaths related to colon cancer, including both genders, have more than doubled since 2020.  This is likely due to late diagnosis, as symptoms are often presented at an advanced stage of the disease. Poor access to prevention screenings and treatment options, and a lack of awareness, particularly in rural areas, have contributed significantly to the overall survival rate.

Risk factors Various risk factors are associated with cancer. It can be caused by internal factors such as genetic mutations as well as external factors such as lifestyle choices and environmental factors. Cancer arises when a single cell mutates and abnormal cell growth develops, which eventually spreads into other tissues and organs. Exposure to chemicals or minerals (such as asbestos) may trigger a cell to behave abnormally. Additionally, a lack of physical activity, a diet high in processed food, obesity, alcohol abuse, and smoking are some lifestyle factors that may contribute to or increase the risk of cancer.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

The relationship between the incidence and mortality of leukemia with the HDI and its components.

Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 17.600 % in 2021. This records an increase from the previous number of 16.900 % for 2020. Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 17.050 % from Dec 2000 (Median) to 2021, with 22 observations. The data reached an all-time high of 18.300 % in 2001 and a record low of 16.200 % in 2012. Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Cuba – Table CU.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

BackgroundThis nationwide study examined breast cancer (BC) incidence and mortality rates in Hungary between 2011–2019, and the impact of the Covid-19 pandemic on the incidence and mortality rates in 2020 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary.MethodsOur nationwide, retrospective study included patients who were newly diagnosed with breast cancer (International Codes of Diseases ICD)-10 C50) between Jan 1, 2011 and Dec 31, 2020. Age-standardized incidence and mortality rates (ASRs) were calculated using European Standard Populations (ESP).Results7,729 to 8,233 new breast cancer cases were recorded in the NHIF database annually, and 3,550 to 4,909 all-cause deaths occurred within BC population per year during 2011-2019 period, while 2,096 to 2,223 breast cancer cause-specific death was recorded (CSO). Age-standardized incidence rates varied between 116.73 and 106.16/100,000 PYs, showing a mean annual change of -0.7% (95% CI: -1.21%–0.16%) and a total change of -5.41% (95% CI: -9.24 to -1.32). Age-standardized mortality rates varied between 26.65–24.97/100,000 PYs (mean annual change: -0.58%; 95% CI: -1.31–0.27%; p=0.101; total change: -5.98%; 95% CI: -13.36–2.66). Age-specific incidence rates significantly decreased between 2011 and 2019 in women aged 50–59, 60–69, 80–89, and ≥90 years (-8.22%, -14.28%, -9.14%, and -36.22%, respectively), while it increased in young females by 30.02% (95%CI 17,01%- 51,97%) during the same period. From 2019 to 2020 (in first COVID-19 pandemic year), breast cancer incidence nominally decreased by 12% (incidence rate ratio [RR]: 0.88; 95% CI: 0.69–1.13; 2020 vs. 2019), all-cause mortality nominally increased by 6% (RR: 1.06; 95% CI: 0.79–1.43) among breast cancer patients, and cause-specific mortality did not change (RR: 1.00; 95%CI: 0.86–1.15).ConclusionThe incidence of breast cancer significantly decreased in older age groups (≥50 years), oppositely increased among young females between 2011 and 2019, while cause-specific mortality in breast cancer patients showed a non-significant decrease. In 2020, the Covid-19 pandemic resulted in a nominal, but not statistically significant, 12% decrease in breast cancer incidence, with no significant increase in cause-specific breast cancer mortality observed during 2020.

Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.

Market Dynamics of The Prostate Cancer Therapeutics Market

Key Drivers for The Prostate Cancer Therapeutics Market

Growing Prevalence of Prostate Cancer fuels the Growth of the Prostate Cancer Therapeutics Market

The market for Prostate Cancer therapeutics is anticipated to develop in the future due to the Growing incidence of prostate cancer. According to the National Cancer Institute, the National Institute of Health (The U.S.) depicts that out of roughly 200,000 cases that were reported in 2020, there were 34,000 deaths from prostate cancer, representing a mortality rate of 5.5%. The analysis suggests that 12.1% of men are expected to develop prostate cancer in their lifetime. Thus, the mortality rate increased due to the growing prevalence of prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 299,010 new cases of prostate cancer and about 35,250 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs market. Source:(https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) Therefore, the rising prevalence of prostate cancer is propelling the growth of the prostate cancer therapeutics market, highlighting the urgent need for effective treatment options.

Biotechnological innovation in prostate cancer treatment drugs to Drive the Global Market of Prostate Cancer Therapeutics.

The market for prostate cancer medications is significantly influenced by the Biotechnological research and development innovation in prostate cancer treatment drugs. Recent developments in prostate cancer therapies have integrated several bioinformatics and computational biology applications to attain the best possible cancer treatment. Market participants have discovered a successful way to develop new cures and treatments with a targeted approach that includes whole-genome sequencing, exome profiling, and proteome profiling. For instance, Biopep Solutions Inc. is a privately owned development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. This Canada-based company focuses its efforts on the development of BPS-001, which is a complex, multivalent biologic drug that possesses anti-tumour attributes. There is a huge demand for innovation in the prostate cancer therapeutics market for products that have enhanced survival time, less toxicity, increased progression-free survival, increased efficacy, and lower cost. Source:(https://www.biopeps.com/bps-001-mechanism-of-action/) Therefore, with a growing population of elderly men worldwide, the demand for prostate cancer therapeutics is expected to soar, emphasizing the importance of tailored medical solutions to address this demographic trend.

Restraint Factor for The Prostate Cancer Therapeutics Market

Recurrent/Non-Responsive Prostate Cancer restrains the growth of the Prostate Cancer Therapeutics market.

The challenge of Recurrent/no...

Cancer is a global health problem and one of the leading causes of human death. According to the data released by the International Agency for Research on Cancer (IARC) in 2022, there were 19.3 million new cancer cases and nearly 10 million cancer deaths worldwide in 2020. At the same time, with rising morbidity and mortality, cancer has become the leading cause of death and a major public health problem for the Chinese population. China ranked first in the world in the number of new cancer cases and deaths in 2020. Camptothecin (CPT) , which has extensive antitumor activity, is a natural pentacyclic monoterpene alkaloid isolated from Camptotheca acuminata by Wall and Wani in 1966. In the 1970s, CPT was clinically approved to treat stomach cancer, bladder cancer, and certain types of leukemia. Camptothecin, as a natural drug candidate parent nucleus, has developed so far, and a large number of derivatives have been derived. The CDAD database integrates the latest laboratory data on the inhibition of cancer cells by camptothecin derivatives, as well as the anti-cancer data of camptothecin derivatives in the previously published literature. Each entry contains detailed information about the camptothecin derivatives, such as SMILE, molecular weight, IUPAC designation, median inhibition concentration (IC50), duration of action, target and related literature and patents, etc. This data will contribute to the further development of camptothecin derivatives and promote the anticancer research of camptothecin derivatives.

Immuno Oncology Diagnosis Market Outlook

The global immuno oncology diagnosis market size was valued at $2.5 billion in 2023 and is projected to reach $7.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.7% during the forecast period. This marketÂ’s growth is driven primarily by the rising incidence of cancer and advancements in diagnostic technologies that enable early and precise detection of oncological conditions.

One of the primary growth factors for the immuno oncology diagnosis market is the increasing prevalence of cancer globally. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with approximately 19.3 million new cases and 10 million cancer-related deaths in 2020. The rising cancer incidence necessitates advanced diagnostic solutions to ensure early detection and effective treatment, thereby driving the demand for immuno oncology diagnostics. Additionally, the growing awareness about the importance of early cancer diagnosis among the general population and healthcare providers further fuels market growth.

Another significant growth factor is the advancements in diagnostic technologies. Innovations such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and flow cytometry have revolutionized the field of oncology diagnostics. These technologies offer enhanced accuracy, specificity, and sensitivity in detecting cancer biomarkers, thereby improving diagnostic outcomes. The integration of artificial intelligence (AI) and machine learning in diagnostic tools also holds immense potential for improving diagnostic efficiency and accuracy, further propelling market growth.

The increasing investment in cancer research and development by governments, healthcare organizations, and pharmaceutical companies is also a key driver for the market. Significant funding and grants are being allocated to cancer research initiatives to develop innovative diagnostic and treatment solutions. The collaboration between academic and research institutes, diagnostic laboratories, and biotechnology companies is fostering the development of advanced diagnostic assays, kits, and instruments, thereby contributing to market growth.

Immuno-Oncology is a rapidly evolving field that plays a crucial role in the development of innovative diagnostic and therapeutic solutions for cancer. This area focuses on harnessing the body's immune system to identify and combat cancer cells, offering a promising approach to cancer treatment. The integration of immuno-oncology in diagnostics has led to the development of advanced assays and biomarkers that enhance the precision of cancer detection and monitoring. By understanding the interactions between the immune system and cancer cells, researchers can develop targeted therapies that improve patient outcomes. The continuous advancements in immuno-oncology are expected to drive significant growth in the diagnostic market, providing new opportunities for early detection and personalized treatment strategies.

Regionally, North America holds the largest share of the immuno oncology diagnosis market, attributed to the presence of a well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and significant investment in cancer research. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the increasing prevalence of cancer, improving healthcare infrastructure, and rising awareness about early cancer diagnosis. Europe also holds a significant market share, with countries like Germany, France, and the UK leading in cancer research and diagnostics.

Product Type Analysis

The product type segment of the immuno oncology diagnosis market includes assays, kits, reagents, instruments, and software. Assays are a crucial component in the diagnosis and monitoring of cancer as they provide detailed information about the presence and progression of the disease. These assays are designed to detect specific cancer biomarkers, thus aiding in accurate diagnosis and personalized treatment planning. The increasing demand for early and precise cancer diagnosis is driving the growth of the assays segment. Furthermore, the development of advanced assays with higher sensitivity and specificity is anticipated to boost the market growth.

Kits are another essential product type in the immuno oncology diagnosis

Cancer is rapidly increasing worldwide and urgent global action towards cancer control is required. Consistent with global trends, Canada is expected to experience a near doubling in new cases and cancer deaths between 2020–2040; population growth and ageing being the primary drivers. The projected increased cancer incidence and its associated costs is expected to further exacerbate socioeconomic inequities. Focused actions to prevent cancer, to detect it earlier when more treatable, and, to lower the risk of recurrence, must be prioritized. Almost half of all cancers are preventable, caused by risk factors that are potentially avoidable and modifiable. Integrating cancer prevention with care-based models is necessary and represents the most cost-effective and sustainable approach to control cancer. To be effective, prevention efforts must consider the cancers impacting local populations and understand how community and individual factors interact within the spatial and temporal contexts in which people live. This study is part of the Nova Scotia Community Cancer Matrix project which profiles the cancers impacting communities over time; measuring associations between cancer and socioeconomic status (SES); and determining how the joint spatial distribution of cancers can be used to address inequities, identify priority populations and strengthen prevention efforts. Using Bayesian inference to model spatio-temporal variations in 58,206 cases diagnosed in 301 communities between 2001–2017, across 10 preventable cancer types, we report significant disparities in cancer risk across communities based on sex and community SES. The work highlights the utility of small-area mapping to identify at-risk communities and understand how community-SES impacts risk. It also uncovers significant inequities rooted in the differential distribution of material and social capacity, operating beyond the control of individuals. The approach is implementable to other regions to inform and strengthen prevention efforts aiming at reducing the burden of cancer or that of other diseases.

The Get Data Out programme from the National Disease Registration Service publishes detailed statistics about small groups of cancer patients in a way that ensures patient anonymity is maintained. The 19 cancer sites currently covered by Get Data Out are: ‘Bladder, urethra, renal pelvis and ureter’, ‘Bone’, ‘Brain’, ‘Eye’, ‘Blood cancer (haematological neoplasms)’, ‘Blood cancer (haematological neoplasm) transformations’, ‘Head and neck’, ‘Kaposi sarcoma’, ‘Kidney’, ‘Liver and biliary tract’, ‘Lung, mesothelioma, and other thoracic', Oesophagus and stomach’, ‘Ovary’, ‘Pancreas’, ‘Prostate’, ‘Sarcoma’, ‘Skin tumours’, ‘Soft tissue’, ‘Testes’. Anonymisation standards are designed into the data by aggregation at the outset. Patients diagnosed with a certain type of tumour are divided into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These groups are aimed to be clinically meaningful and differ across cancer sites. For each group of patients, Get Data Out routinely publish statistics about incidence, routes to diagnosis, treatments and survival. This release covers a refresh of the 2013-2020 incidence data plus the addition of the diagnosis years 2021 and 2022 for incidence. It also covers a refresh of the 2013-2020 treatment data plus the addition of the diagnosis year 2021 for treatment statistics. It also covers a refresh of the 2013-2018 routes to diagnosis data plus the addition of the diagnosis years 2019 and 2020 for routes to diagnosis data. In this release some of our group names have been revised to more concise or more meaningful names. This better aligns us with other NDRS publications. For example, the group which was previously called 'Ovary, fallopian tube and primary peritoneal carcinomas' is now called 'Ovary', and the group which was previously called 'Haematological malignancies' is now called 'Blood cancer (haematological neoplasms)'. Finally, this release includes some new columns in the incidence data. As well as publishing crude incidence rates, we are now publishing age gender standardised incidence rates along which their upper and lower confidence intervals. This will allow for better international comparison of our groups. We have also added 50 new incidence columns which break down the incidence in the whole group by different patient characteristics. These are five-year-age and gender, broad ethnicity group, and deprivation quintile. For a specific GDO group therefore (row in our output data), a user will be able to identify the incidence for that group as a whole and then the incidence in, for example, the '65-69 male' group, the '40-44 female' group, the 'Black' group, or the 'Deprivation quintile 4' group. All releases and documentation are available on the Get Data Out dashboard. Before using the data, we recommend that you read the 'Introduction', 'FAQs' and 'Known limitations' tabs. The data is available in an open format for anyone to access and use. We hope that by releasing anonymous detailed data like this we can help researchers, the public and patients themselves discover more about cancer. If you have feedback or any other queries about Get Data Out, please email us at NDRSenquires@nhs.net and mention 'Get Data Out' in your email.

Around 10% of all cancer cases are colorectal cancer, making it the second most common cause of cancer-related deaths globally and the third most common type of cancer overall. The World Health Organization (WHO) estimates that by 2040, there will be 3.2 million new colorectal cancer (CRC) cases and 1.6 million deaths worldwide, up from an expected 1.9 million new cases and 935,000 deaths in 2020, with a large percentage of deaths attributable to metastatic disease. The colorectal cancer epidemiology forecast report will provide a comprehensive analysis of the disease's prevalence, incidence trends, and patient demographics across key regions.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Background and aimThis study aims to analyze the worldwide prevalence, mortality rates, and disability-adjusted life years (DALYs) attributed to breast cancer in women between 1990 and 2019. Additionally, it seeks to forecast the future trends of these indicators related to the burden of breast cancer in women from 2020 to 2030.MethodsData from the Global Burden of Disease Study (GBD) 2019 was analyzed to determine the age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) of DALYs due to breast cancer in women across 204 countries and territories from 1990 to 2019. Socio-economic development levels of countries and regions were assessed using Socio-demographic Indexes, and trends in the burden of breast cancer in women worldwide from 2020 to 2030 were projected using generalized additive models (GAMs).ResultsThe estimated annual percentage change (EAPC) in the ASIR breast cancer in women globally was 0.36 from 1990 to 2019 and is expected to increase to 0.44 from 2020 to 2030. In 2019, the ASIR of breast cancer in women worldwide was 45.86 and is projected to reach 48.09 by 2030. The burden of breast cancer in women generally rises with age, with the highest burden expected in the 45–49 age group from 2020 to 2030. The fastest increase in burden is anticipated in Central sub-Saharan Africa (EAPC in the age-standardized death rate: 1.62, EAPC in the age-standardized DALY rate: 1.52), with the Solomon Islands (EAPC in the ASIR: 7.25) and China (EAPC in the ASIR: 2.83) projected to experience significant increases. Furthermore, a strong positive correlation was found between the ASIR breast cancer in women globally in 1990 and the projected rates for 2030 (r = 0.62).ConclusionThe anticipated increase in the ASIR of breast cancer in women globally by 2030 highlights the importance of focusing on women aged 45–49 in Central sub-Saharan Africa, Oceania, the Solomon Islands, and China. Initiatives such as breast cancer information registries, raising awareness of risk factors and incidence, and implementing universal screening programs and diagnostic tests are essential in reducing the burden of breast cancer and its associated morbidity and mortality.